GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer ...

Modified vaccinia Ankara immunization in nonhuman primate models of lethal mpox virus infection, although effective to some extent, has been linked to breakthrough lesions and throat swab viremia.

Chatham, New Jersey Wednesday, November 6, 2024, 18:00 Hrs [IST] ...

Pexa-Vec (pexastimogene devacirepvec) is a modified vaccinia virus that has been engineered to express immune-boosting cytokine GM-CSF. The PHOCUS trial of Pexa-Vec was terminated on the advice of ...

The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in ...

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant ...

A NEW strain of the mpox virus has been detected in the UK, and now an expert has warned not to confuse the symptoms with ...

Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Good afternoon, ladies and gentlemen, and welcome to the SIGA ...

The Department of Microbiology and Immunology is one of 25 departments within the RSOM. It is dedicated to advancing the ...

Protein vaccines are composed of purified or recombinant proteinaceous antigens from a pathogen, such as a bacterium or virus. When administered, a protective immune response is elicited against ...

myvac is a viral vector (MVA—Modified Vaccinia Ankara) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. myvac-derived products are designed to ...